BCTX - BriaCell Therapeutics Corp.

QQQ $ 490.95 $ 4.06 (0.83 %)

DIA $ 392.84 $ -0.46 (-0.12 %)

SPY $ 551.46 $ 2.45 (0.45 %)

TLT $ 91.86 $ 1.19 (1.31 %)

GLD $ 217.99 $ 2.43 (1.13 %)

Previous Close

$ 1

Open

$ 1.02

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 1.01 - $ 1.05

52 Week Range

$ 0.95 - $ 7.18

Volume

54,166

Average Volume

Market Cap

15.98M

Beta (5Y Monthly)

$ 0.36

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	06-14-2024	04-30-2024	10-Q
2	03-18-2024	01-31-2024	10-Q
3	12-14-2023	10-31-2023	10-Q
4	10-25-2023	07-31-2023	10-K
5	06-14-2023	04-30-2023	10-Q
6	03-16-2023	01-31-2023	10-Q
7	12-14-2022	10-31-2022	10-Q
8	10-28-2022	07-31-2022	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Reiterates Buy on Bria...
06/04/2024 10:54:41

HC Wainwright & Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and maintains $18 pri...

BriaCell Presents Clinical Efficacy Data O...
06/03/2024 12:29:16

BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMT™ PFS...

BriaCell Starts Patient Enrollment In Firs...
05/30/2024 12:09:54

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage b...

BriaCell Therapeutics Announces Clinical S...
05/28/2024 12:28:39

BriaCell Doubles Progression-Free-Survival...
05/24/2024 12:05:28

83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS m...

HC Wainwright & Co. Reiterates Buy on Bria...
05/24/2024 11:24:17

HC Wainwright & Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and maintains $18 pri...

BriaCell Therapeutics Announces Pricing Of...
05/15/2024 12:16:40

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage b...

BriaCell 2024 AACR Preclinical Poster Conf...
04/10/2024 12:10:24

Preclinical data shows that BriaCell's Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via mul...

BriaCell Highlights Data For Antibody-Drug...
04/09/2024 12:49:03

PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of controls i...

BriaCell Receives And Executes Letter Of I...
03/07/2024 13:02:09

Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+...

BriaCell To Present Clinical Data In Centr...
03/06/2024 13:14:01

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage b...

BriaCell Provides Update On Alleged Illega...
02/27/2024 13:10:39

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage b...

BriaCell Reports Prelim Disease Control Ra...
02/07/2024 13:03:53

Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell's pivotal ...

Briacell Therapeutics Filed For Mixed Shel...
01/22/2024 22:04:01

-S-3

BriaCell Images Confirm Robust Anti-Tumor ...
01/04/2024 13:46:08

Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cycles Powerful anti-tumor response associa...

HC Wainwright & Co. Reiterates Buy on Bria...
12/28/2023 16:30:06

HC Wainwright & Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and maintains $18 pri...

BriaCell Reports 71% Central Nervous Syste...
12/28/2023 13:58:25

71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clini...

briacell-therapeutics-cancer-drug-shows-preliminary-survival-clinical-benefit-in-pretreated-patients

BriaCell Therapeutics' Cancer Drug Shows P...
12/20/2023 17:37:50

BriaCell Therapeutics Corp (NASDAQ: BCTX) reported preliminary survival and clinical benefit data in a new subset of advanced b...

BriaCell Therapeutics Reports Preliminary ...
12/20/2023 13:42:58

In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell's combination re...

BriaCell Highlights Outstanding Topline Su...
12/06/2023 14:33:54

Median overall survival of 13.4 months in patients treated with the Bria-IMT™ combination regimen (vs. 6.7-9.8 months for simil...

CLASS ACTION DEADLINES - JOIN NOW!

07/05/2024 AXT, Inc. (AXTI)

07/05/2024 Altimmune, Inc. (ALT)

07/09/2024 Li Auto Inc. (LI)

07/12/2024 Inari Medical, Inc. (NARI)

07/12/2024 Sprout Social, Inc. (SPT)

07/15/2024 UnitedHealth Group Inc. (UNH)

07/16/2024 Teladoc Health, Inc. (TDOC)

07/16/2024 Vestis Corporation (VSTS)

07/22/2024 Cambium Networks Corporation (CMBM)

07/22/2024 Biogen Inc. (BIIB)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)

BCTXBriaCell Therapeutics Corp.

Nasdaq briacell.com

$ 1.03 $ -0.01 (-0.99 %)

Wednesday, 03-Jul-2024 11:55:56 EDT